Editor, Scrip & Pink Sheet, covering pharmaceutical and business news and analysis; views expressed are purely my own.

Read Full Bio →


Eleanor has been Editor of Scrip Intelligence since 2014. She has worked on the title since 2000, reporting and analysing all aspects of the global pharma industry from M&A and partnering, financial and strategy news and trends through R&D to market access, policy and regulation. She has ...

Search Tweets

Twitter Feed

@ScripEleanor — 1,934 followers, 2,771 tweets

Sep 12, 2017

RT @CitelineHeidi: Today's webinar at Informa Pharma Intelligence: PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology Reg… https://lnkd.in/eeWqrmf 

Sep 12, 2017

RT @datamonitor_MH: Interested to see if $MRK decides to follow $JNJ and drop MK-3682B. No clear way to differentiate in #HCV except further price decreases

Aug 30, 2017

Also, Almirall recently replaced US derma biz head White with ex Allergan/Depomed Ron Menezes after profit warning  https://scrip.pharmamedtechbi.com/SC099201/Almiralls-Perfect-Storm-How-Will-It-Recover 

Aug 30, 2017

2016 Frying pan to 2017 fire: Guenter leaves Sanofi CV/diabetes to head Almirall w/ its US derma probs. @stenstovall in @PharmaScrip 2016: https://t.co/kBiBFXjADb

Aug 30, 2017

RT @_rjw: This is why people should do better powered phase 2 trials - and then quit if they fail. Phase 3 is never better.  https://twitter.com/JohnCendpts/status/902860153971671040 

Show more